# InflaRx N.V. (IFRX)

> Source: Nexqual · https://nexqual.com/IFRX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, InflaRx N.V. (IFRX), nexqual.com/IFRX" · informational, not investment advice.

**Price:** USD 1.44 (-2.70% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.48 · day 1.43–1.53 · 52w 0.8–2.95 · market cap $212M · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 7.67 (range 2.92–13.64).
- Total return with dividends: 1Y +16.1% vs S&P 500 +18.1%; 5Y -41.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.05, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 7.67 (low 2.92, high 13.64).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | Needham | Initiated | Buy | $8 |
| 2026-08-07 | Cantor Fitzgerald | Target raised | Overweight | $4 → $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +16.1% | -41.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +16.2% | -10.2% |
| Volatility (annualized) | 93.0% | 114.7% |
| Max drawdown | -50.3% (Oct 2025→Feb 2026) | -86.0% (Nov 2021→Jun 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IFRX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt